By Joseph Harvey
February 20, 2017
Ceva Animal Health has launched a new live monovalent poultry vaccine in the US.
The new vaccine – Cevac IBron – is indicated to combat the Georgia strains of infectious bronchitis virus (IBV) in poultry. Cevac IBron can be used in healthy chickens one day of age or older.
Ceva said the vaccine is the first and only licensed product available to tackle multiple variants of IBV.
IBV continuously mutates, requiring producers to adapt vaccine regimens to prevent and fight outbreaks. IBV is highly contagious and affects both the respiratory and uro-genital tract. The virus can cause respiratory disease, a decline in egg production, poor weight gain and kidney disease.
Zoetis also offers a live vaccine for the GA 08 strain of IBV in poultry. Poulvac Bron GA 08 is indicated for the vaccination of healthy chickens one day of age or older and was approved by the USDA in August 2014.
Kristi Moore Dorsey, vice president of R&D at Ceva, said: "Ceva responded to the needs of the customer and worked closely with the poultry producers and the US government to accelerate development, licensure and distribution of Cevac IBron to protect against GA08 and GA13 isolates of IBV."
Gary Baxter, vice president of sales and marketing, added: "Given the increasing presence and impact of IBV, we are excited and confident Cevac IBron will provide the much-needed protection our customers need."
Other vaccines already available for IBV in Ceva's portfolio protect against the Massachusetts, Arkansas and Connecticut serotypes of the virus.
Earlier this year, Ceva also gained vaccines for other species after finalizing the acquisition of a range of products divested by Boehringer Ingelheim and Merial as part of their merger. These products included vaccines for cattle and swine, which were immediately available through Ceva subsidiaries or distributors with no interruption of supply.